KPW
CCXI

Kore Private Wealth’s ChemoCentryx, Inc. CCXI Stock Holding History

Kore Private Wealth’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,000
Closed -$28K – 830
2019
Q1 		$28K Hold
2,000
– – 0.01% 469
2018
Q4 		$22K Buy
+2,000
New +$21.1K 0.01% 486

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kore Private Wealth's CCXI Position: Q2 2019 in Review

Kore Private Wealth sold out of ChemoCentryx, Inc. (CCXI) in Q2 2019, closing a stake of 2,000 shares — an estimated $28K sold.

Kore Private Wealth first reported a position in CCXI in Q4 2018 and held it in 2 quarters. The position peaked at $28K in Q1 2019. 117 funds tracked by Wall St. Rank hold CCXI as of Q2 2019.

  • Kore Private Wealth reported no remaining ChemoCentryx, Inc. position as of Q2 2019 after selling out during the quarter.
  • Kore Private Wealth sold 2,000 ChemoCentryx, Inc. shares in Q2 2019, an estimated $28K.
  • Kore Private Wealth first reported a position in ChemoCentryx, Inc. in Q4 2018 and held it in 2 quarters.
  • Kore Private Wealth's ChemoCentryx, Inc. position peaked at $28K in Q1 2019.
  • 117 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2019.

Based on Kore Private Wealth's 13F filing for Q2 2019, filed 14 Aug 2019.